Form 4: Centessa CPO Sells Shares After Option Exercise

Centessa Pharmaceuticals' Chief People Officer, Karen M. Anderson, exercised stock options and subsequently sold a substantial number of shares under a pre-arranged trading plan.

Summary

• Karen M. Anderson, Chief People Officer of Centessa Pharmaceuticals plc (CNTA), reported transactions on March 13, 2026.
• Anderson exercised options to acquire 109,398 Ordinary Shares at an exercise price of $4.01 per share.
• Following the option exercise, Anderson sold a total of 120,029 Ordinary Shares (107,961 shares and 12,068 shares) under a Rule 10b5-1 trading plan adopted on November 12, 2025.
• The first block of 107,961 shares was sold at a weighted average price of $26.1505, with prices ranging from $25.75 to $26.705.
• The second block of 12,068 shares was sold at a weighted average price of $27.1328, with prices ranging from $26.805 to $27.455.
• After these transactions, Anderson beneficially owns 62,085 Ordinary Shares directly and holds options for 134,637 additional Ordinary Shares.
• The options exercised were part of a grant where 25% vested on December 1, 2023, and the remaining 75% vest in 36 monthly installments thereafter.

Sentiment

Score: 6

Explanation: StockSavvy.ai views this as a neutral to slightly positive event. While it involves insider selling, it's a routine transaction for executive compensation, executed under a 10b5-1 plan, and reflects the executive monetizing vested options at a significant profit, which is a positive for the individual.

Positives

• The Chief People Officer realized significant gains by exercising options at $4.01 and selling shares at weighted average prices of $26.1505 and $27.1328, indicating a substantial profit from her compensation package.

Negatives

• The sale of a significant number of shares by a key executive, even under a pre-arranged plan, could be perceived as a lack of conviction in the company's near-term stock price by some investors.

Risks

• No specific risks were detailed in this Form 4 filing, which primarily reports executive stock transactions.

Future Outlook

NA

Industry Context

StockSavvy.ai notes that executive stock option exercises and subsequent sales, particularly when conducted under a Rule 10b5-1 trading plan, are a common and routine aspect of executive compensation and personal financial management within the pharmaceutical and biotechnology industries. These plans allow insiders to sell shares at pre-determined times or prices, mitigating concerns about trading on material non-public information.

Stakeholder Impact

• Shareholders may observe the Chief People Officer's decision to monetize a portion of her equity compensation, which is a common practice for executives.

Key Dates

Recommendation

A single Form 4 filing detailing an executive's exercise of stock options and subsequent sale of shares under a pre-arranged 10b5-1 plan is generally considered a routine event. It does not typically provide sufficient new information to warrant a change in an investment recommendation. The transaction reflects personal financial planning and compensation realization rather than a fundamental shift in the company's outlook.

Keywords

Centessa Pharmaceuticals, CNTA, Form 4, Insider Trading, Stock Options, Share Sale, Executive Compensation, Rule 10b5-1 Plan